Répartition des tâches
par lot de travail (WP), en mois du projet (M3 à M60).
| Tâche | 2024 | 2025 | 2026 | 2027 | 2028 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M3 | M6 | M9 | M12 | M15 | M18 | M21 | M24 | M27 | M30 | M33 | M36 | M39 | M42 | M45 | M48 | M51 | M54 | M57 | M60 | ||
| WP0 | T0.1 - Scientific coordination | ||||||||||||||||||||
| T0.2 - Financial, administrative and contractual management | |||||||||||||||||||||
| T0.3 - Dissemination and Communication | |||||||||||||||||||||
| WP1 | T1.1 - Bacteriophage anti-PA isolation | ||||||||||||||||||||
| T1.2 - Bacteriophage anti-PA characterization/selection | |||||||||||||||||||||
| T1.3 - Description of emergence of bacterial resistance | |||||||||||||||||||||
| T1.4 - Phage anti-PA training | |||||||||||||||||||||
| WP2 | T2.1 - Selection of candidate bacterial strains for anti-PA TP amplification | ||||||||||||||||||||
| T2.2 - Optimization of anti-PA TP amplification processes | |||||||||||||||||||||
| WP3 | T3.1 - TP anti-SE, -EC, -PA purification/formulation process development | ||||||||||||||||||||
| T3.2 - Production/purification for PST | |||||||||||||||||||||
| T3.3 - Production/purification for preclinical trials | |||||||||||||||||||||
| T3.4 - Production/purification for clinical trials | |||||||||||||||||||||
| T3.5 - Conditioning and quality controls | |||||||||||||||||||||
| WP4 | T4.1 - Fine tuning of design/composition of medical devices | ||||||||||||||||||||
| T4.2 - Pharmacokinetic/Pharmacodynamic modeling | |||||||||||||||||||||
| T4.3 - Certification of bone substitutes and smart spacers | |||||||||||||||||||||
| T4.4 - Production of medical devices for tests, preclinical and clinical trials | |||||||||||||||||||||
| WP5 | T5.1 - Tox/Tol preclinical trial for anti-SE TP | ||||||||||||||||||||
| T5.2 - Tox/Tol preclinical trial for anti-EC TP | |||||||||||||||||||||
| T5.3 - Tox/Tol preclinical trial for anti-PA TP | |||||||||||||||||||||
| WP6 | T6.1 - Set up of a S. aureus-induced tissue cage infection model in mice | ||||||||||||||||||||
| T6.2 - Efficacy evaluation of the bone substitute loaded with TP in PJI mice model | |||||||||||||||||||||
| T6.3 - Set up of a cutting-edge SA prosthetic joint infection model in rabbits | |||||||||||||||||||||
| T6.4 - Efficacy evaluation of the bone substitute loaded with TP in PJI rabbit model | |||||||||||||||||||||
| WP7 | T7.1 - Development of standardized and ready-to-use panels for phage susceptibility test | ||||||||||||||||||||
| T7.2 - Development/validation of TP Susceptibility Test using REVEAL technology | |||||||||||||||||||||
| T7.3 - Evaluation of synergistic effect of TP/ATB using REVEAL Technology | |||||||||||||||||||||
| WP8 | T8.1 - Data control arm conception | ||||||||||||||||||||
| T8.2 - Regulatory aspect and clinical study authorization | |||||||||||||||||||||
| T8.3 - Patient inclusions and follow up in BOSAP clinical study | |||||||||||||||||||||
| T8.4 - Patient inclusions and follow up in SMART SPACER clinical study | |||||||||||||||||||||
Échelle : mois du projet (M), de M3 à M60. Chaque barre représente la période active d’une tâche au sein de son lot de travail (WP).